Gaining knowledge on human responses against the influenza virus will help us in treating influenza infections and lead to more effective vaccines. Additionally, it might also lead to identification of individuals that have a high risk of morbidity…
ID
Bron
Verkorte titel
Aandoening
RA, reuma, Rheumatoid Arthritis
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
1. Frequency of in-vitro responding clones during follow-up of the new influenza A/H1N1 virus infection;<br>
2. Functional characterization of individual responding clones;<br>
3. Correlation of T-cell responses with antibody responses.
Achtergrond van het onderzoek
Country of recruitment: the Netherlands.
We want to study otherwise healthy volunteers undergoing new influenza A/H1N1 infection.
We will combine in-vitro stimulation assays and High Throughput Sequencing to identify, quantify and phenotype the clones that play a functional role in influenza infections and follow them over time.
Doel van het onderzoek
Gaining knowledge on human responses against the influenza virus will help us in treating influenza infections and lead to
more effective vaccines. Additionally, it might also lead to identification of individuals that have a high risk of morbidity and even mortality during infection.
Onderzoeksopzet
Day 0-4, 7, 14, 28, 56, 84, 112 and 140.
Onderzoeksproduct en/of interventie
We want to study otherwise healthy volunteers undergoing new influenza A/H1N1 infection.
We will combine in-vitro stimulation assays and High Throughput Sequencing to identify, quantify and phenotype the clones that play a functional role in influenza infections and follow them over time.
Publiek
A.N. Scholten
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5662337
a.n.scholten@amc.uva.nl
Wetenschappelijk
A.N. Scholten
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5662337
a.n.scholten@amc.uva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Able and willing to give written informed consent;
2. Age 18-85 years;
3. PCR-confirmed new influenza A/H1N1 infection with symptoms present for less than 4 days.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Therapy within the previous 60 days with:
A. Any experimental drug;
B. Monoclonal antibodies;
C. Growth factors;
D. Other anti-cytokines.
2. Therapy within the previous 28 days with:
A. Anti-viral medication;
B. Parenteral corticoid injections;
C. Oral corticosteroid therapy exceeding a prednisone equivalent of 10 mg daily.
3. Any clinically significant medical condition;
4. Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2352 |
| NTR-old | NTR2459 |
| Ander register | MEC AMC : 10/084 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |